Belite Bio, Inc
BLTE
$90.37
$2.663.03%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 12.42M | 7.23M | 6.82M | 6.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 43.84M | 33.12M | 31.67M | 31.43M |
| Operating Income | -- | -43.84M | -33.12M | -31.67M | -31.43M |
| Income Before Tax | -- | -42.11M | -32.60M | -31.62M | -31.42M |
| Income Tax Expenses | -- | 6.00K | 9.00K | 9.00K | 10.00K |
| Earnings from Continuing Operations | -- | -42.12 | -32.61 | -31.63 | -31.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -42.12M | -32.61M | -31.63M | -31.43M |
| EBIT | -- | -43.84M | -33.12M | -31.67M | -31.43M |
| EBITDA | -- | -43.72M | -33.01M | -31.59M | -31.37M |
| EPS Basic | -- | -1.41 | -1.18 | -1.24 | -1.27 |
| Normalized Basic EPS | -- | -0.15 | -0.15 | -0.15 | -0.17 |
| EPS Diluted | -- | -1.41 | -1.18 | -1.24 | -1.27 |
| Normalized Diluted EPS | -- | -0.15 | -0.15 | -0.15 | -0.17 |
| Average Basic Shares Outstanding | -- | 117.89M | 111.09M | 102.37M | 98.99M |
| Average Diluted Shares Outstanding | -- | 117.89M | 111.09M | 102.37M | 98.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |